Eventide Asset Management LLC Has $23.08 Million Holdings in Veracyte, Inc. (NASDAQ:VCYT)

Eventide Asset Management LLC grew its holdings in Veracyte, Inc. (NASDAQ:VCYT - Free Report) by 20.2% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 677,883 shares of the biotechnology company's stock after buying an additional 113,883 shares during the quarter. Eventide Asset Management LLC owned 0.87% of Veracyte worth $23,075,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Veracyte by 3.7% during the first quarter. Vanguard Group Inc. now owns 7,384,871 shares of the biotechnology company's stock valued at $163,649,000 after purchasing an additional 266,660 shares in the last quarter. William Blair Investment Management LLC raised its stake in Veracyte by 67.4% during the second quarter. William Blair Investment Management LLC now owns 1,241,671 shares of the biotechnology company's stock worth $26,907,000 after acquiring an additional 500,020 shares in the last quarter. Granite Investment Partners LLC lifted its holdings in shares of Veracyte by 2.1% during the second quarter. Granite Investment Partners LLC now owns 934,994 shares of the biotechnology company's stock valued at $20,261,000 after acquiring an additional 19,244 shares during the period. Fiera Capital Corp boosted its stake in shares of Veracyte by 1.2% in the 2nd quarter. Fiera Capital Corp now owns 625,536 shares of the biotechnology company's stock valued at $13,555,000 after purchasing an additional 7,219 shares in the last quarter. Finally, Point72 Asset Management L.P. bought a new stake in shares of Veracyte in the 2nd quarter worth about $12,279,000.

Insider Buying and Selling at Veracyte

In other news, Director Evan/ Fa Jones sold 5,173 shares of the business's stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $35.23, for a total value of $182,244.79. Following the completion of the transaction, the director now owns 34,343 shares of the company's stock, valued at $1,209,903.89. The trade was a 13.09 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Jonathan Wygant sold 5,032 shares of the firm's stock in a transaction on Wednesday, November 27th. The stock was sold at an average price of $42.89, for a total value of $215,822.48. Following the sale, the chief accounting officer now directly owns 42,313 shares in the company, valued at $1,814,804.57. The trade was a 10.63 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 15,684 shares of company stock valued at $561,232. 1.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on VCYT shares. Morgan Stanley lifted their price objective on Veracyte from $26.00 to $28.00 and gave the company an "underweight" rating in a research report on Monday, November 18th. Guggenheim started coverage on Veracyte in a report on Thursday, October 10th. They issued a "buy" rating and a $40.00 price target for the company. Leerink Partners increased their price objective on shares of Veracyte from $35.00 to $40.00 and gave the stock an "outperform" rating in a report on Thursday, October 17th. Wolfe Research initiated coverage on shares of Veracyte in a research note on Friday, November 15th. They issued an "outperform" rating and a $50.00 target price for the company. Finally, Scotiabank upped their target price on shares of Veracyte from $40.00 to $44.00 and gave the stock a "sector outperform" rating in a research report on Friday, November 8th. One analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Veracyte currently has a consensus rating of "Moderate Buy" and a consensus target price of $41.25.

Veracyte Trading Up 0.1 %

Shares of VCYT traded up $0.06 on Friday, reaching $42.95. 490,418 shares of the company's stock were exchanged, compared to its average volume of 770,434. The business has a 50 day moving average price of $35.70 and a two-hundred day moving average price of $29.03. Veracyte, Inc. has a 12 month low of $18.61 and a 12 month high of $44.16. The stock has a market capitalization of $3.33 billion, a P/E ratio of -286.33 and a beta of 1.67.

Veracyte (NASDAQ:VCYT - Get Free Report) last issued its earnings results on Wednesday, November 6th. The biotechnology company reported $0.19 EPS for the quarter, beating the consensus estimate of $0.03 by $0.16. Veracyte had a negative net margin of 2.18% and a positive return on equity of 3.02%. The company had revenue of $115.86 million during the quarter, compared to analysts' expectations of $109.81 million. During the same quarter in the previous year, the company posted ($0.03) EPS. The business's revenue for the quarter was up 28.6% compared to the same quarter last year. Equities research analysts predict that Veracyte, Inc. will post 0.32 EPS for the current year.

Veracyte Profile

Veracyte, Inc operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis.